Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives

British Journal of Haematology

Volumn 97, Issue 1, 1997, Pages 233-238

  Rosing, J ^a   Tans, G ^b   Nicolaes, G A F ^b   Thomassen, M C L G D ^b   Van Oerle, R ^b   Van Der Ploeg, P M E N ^b   Heijnen, P ^b   Hamulyak, K ^b   Hemker, H C ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

APC resistance; oral contraceptives; venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL; GESTODENE; LEVONORGESTREL; LYNESTRENOL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

EID: 0030934739     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.192707.x     Document Type: Article

References (29)

1. Altman, D.G. (1941) Practical Statistics for Medical Research. Chapman & Hall, London.
2. Beauchamp, N.J., Daly, M.E., Cooper, P.C., Preston, F.E. & Peake, I.R. (1994) Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet, 344, 694-695.
3. Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R. J., de Ronde, H., van der Velden, P.A. & Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 64-67.
4. Bloemenkamp, K.W., Rosendaal, F.R., Heimerhorst, F.M., Buller, H.R. & Vandenbroucke, J.P. (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 346, 1593-1596.
5. Dahlback, B., Carlsson, M. & Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America, 90, 1004-1008.
6. de Ronde, H. & Bertina, R.M. (1994) Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thrombosis and Haemostasis, 72, 880-886.
7. Duchemin, J., Pittet, J., Tartary, M., Beguin, S., Gaussem, P., Athen-Gelas, M. & Aiach, M. (1994) A new method based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thrombosis und Haemostasia, 71, 331-338.
8. Esmon, C.T. (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. Journal of Biological Chemistry, 264, 4743-4746.
9. Greer, L.A. (1994) Haemostasis and Thrombosis, pp. 1327-1338. Churchill Livingstone, Edinburgh.
10. Griffin, J.H., Evatt, B., Wideman, C. & Fernandez. J.A. (1993) Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood, 82, 1989-1993.
11. Griffin, J.H., Evatt, B., Zimmerman, T.S., Kleiss, A.J. & Wideman, C. (1981) Deficiency of protein C in congenital thrombotic disease. Journal of Clinical Investigation, 68, 1370-1373.
12. Hemker, H.C. & Beguin, S. (1995) Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thrombosis and Haemostasis, 56, 9-17.
13. Hemker, H.C., Willems, G.M. & Beguin, S. (1986) A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of the thrombin decay processes. Thrombosis and Haemostasis, 56, 9-17.
14. Henkens, C.M.A., Bom. V.J.J., Seinen, A.J. & van der Meer, J. (1995) Sensitivity to activated protein C: influence of oral contraceptives and sex. Thrombosis and Haemostasis, 73, 402-404.
15. Hirsch, J., Piovella, F. & Pini, M. (1989) Congenital antithrombin III deficiency: incidence and clinical features. American Journal of Medicine, 87, 34S-38S.
16. Jordan, W.M. (1961) Pulmonary embolism. Lancet, ii. 1146-1147.
17. Koster, T., Rosendaal, F.R., de Ronde, H., Briet, E., Vandenbroucke, J.P. & Bertina, R.M. (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet, 342, 1503-1506.
18. Newton, J.R. (1995) Classification and comparison of oral contraceptives containing new generation progestagens. Human Reproduction Update, 1, 231-263.
19. Nicolaes, G.A.E. Tans, G., Thomassen, M.C.L.G.D., Hemker, H.C., Pabinger, I., Varadi, K., Schwarz, H.P. & Rosing, J. (1995) Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. Journal of Biological Chemistry, 270, 21158-21166.
20. Nicolaes, G.A.F., Thomassen, M.C.L.G.D., van Oerle, R., Hamulyak, K., Hemker, H.C., Tans, G. & Rosing, J. (1996) A prothrombinase-based assay for detection of resistance to activated protein C. Thrombosis and Haemostasis, 76, 404-410.
21. Olivieri, O., Friso, S. & Manzato, F. (1995) Resistance to activated protein C in healthy women taking oral contraceptives. British Journal of Haematology, 91, 465-470.
22. Rosendaal, F.R., Koster, T., Vandenbroucke, J.P. & Reitsma, P.H. (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood, 85, 1504-1508.
23. Schwarz, H.P. Fischer, M., Hopmeier, P., Batard, M.A. & Griffin, J.H. (1984) Plasma protein S deficiency in familial thrombolic disease. Blood, 64, 1297-1300.
24. Speroff, L. & DeCherney, A. (1993) Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstetrics and Gynecology, 81, 1034-1047.
25. Spitzer, W.O., Lewis, M.A., Heinemann, L.A., Thorogood, M. & MacRae, K.D. (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case - control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. British Medical Journal, 312, 83-88.
26. Svensson, P.J. & Dahlback, B. (1994) Resistance to activated protein C as a basis for venous thrombosis. New England Journal of Medicine, 330, 517-522.
27. Vandenbroucke, J.P., Koster, T., Briet, E., Reitsma, P.H., Bertina, R.M. & Rosendaal, F.R. (1994) Increased risk of venous thrombosis in oral-contraceptives users who are carriers of factor V Leiden mutation. Lancet, 344, 1453-1457.
28. W.H.O. (1995a) World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case - control study. Lancet, 346, 1575-1582.
29. W.H.O. (1995b) World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 346, 1582-1588.